P
robiotics are live microorganisms which when administered in adequate amounts confer a health benefit on the host (33) . The genus Bifidobacterium, a predominant member of the human gut microbiota, includes some strains which are widely used as probiotic bacteria (14) . In this context, it is known that probiotics play an important role in the maintenance of the gastrointestinal barrier function (12, 18, 29) , as well as exhibiting health properties through the modulation of both mucosal and systemic immunity under healthy or pathogenic conditions (6, 51) .
Because of its strategically located anatomical situation, intestinal mucosa is of key importance for the communication between gut microbiota and immune cells of the gut-associated lymphoid tissue (GALT). Particularly, the layer of epithelial cells, mainly composed of enterocytes, plays an active role in the modulation of innate and adaptive immune responses (49) . Intestinal epithelial cells can identify a wide variety of microorganisms, or their components, through membrane-bound pattern recognition receptors and could release chemokines, low-molecular-weight chemotactic cytokines relevant for the directional trafficking and the recruitment of specific immune cells. Specifically, chemokines have been described as being important in the recruitment and retention in different tissues of specific T-cell subsets expressing specific chemokine receptors (31) . In addition, the chemokine receptor expression by T cells differs among the naïve, memory, effector, and regulatory T-cell subsets, depending on their activation status (37) .
The immune cells localized in the GALT, such as dendritic cells (DCs) and T lymphocytes, constitute the first point of contact between gut commensals, or orally ingested probiotics, and our immune system (34, 50) . In this sense, it has been described how distinct strains of Bifidobacterium species can induce different maturation and cytokine production patterns in DCs in a strainspecific manner (20, 27 ) that may direct the polarization of naïve CD4 ϩ T cells toward different effector or regulatory T-cell subsets (4, 26, 52) . In particular, nowadays there is increasing evidence regarding the ability of probiotic bacteria to induce CD25 high FOXP3
ϩ regulatory T cells (Treg cells) from naïve precursors (7, 10, 11, 26, 44) . Since Treg cells can suppress uncontrolled effector responses to self and intraluminal antigens (5), the recruitment or induction of Treg cells by probiotics could have a beneficial effect on allergy and autoimmune diseases. Moreover, diverse studies have suggested that Treg cells could undergo selective migration, controlled by distinct signals from chemokines and their receptors, to sites where regulation is required (48) .
Interestingly, we recently reported that exposing DCs to Bifidobacterium bifidum LMG13195 in vitro induces the polarization of naïve CD4 ϩ lymphocytes into functional CD25 high FOXP3
ϩ Treg cells (26) . However, nothing is known about the possible effect of this strain on intestinal mucosa. Thus, in the present work we wanted to study the response of human intestinal epithelial cells to this strain and its potential immune regulatory effect. For this purpose, we exposed HT29 cells to B. bifidum LMG13195 (and to Bifidobacterium breve IPLA 20004 as a control) to determine, first, the influence on HT29 gene expression, and second, the effect on chemokine receptors and Treg markers of human peripheral CD4 ϩ lymphocytes. In addition, the effect on enterocyte monolayer integrity was evaluated. For the analysis of the effects on HT29 cell line monolayer integrity, UV-killed bacteria were obtained as previously described (26) . The use of UV-killed bacteria was necessary in order to avoid acidification of the culture medium due to the long incubation times and the consequent monolayer damage. UV-treated bacterial suspensions were distributed in single-use aliquots, frozen in liquid N 2 , and stored at Ϫ80°C until use.
MATERIALS AND METHODS

Bacterial
To evaluate the effects of the interaction between Bifidobacterium strains and HT29 cells on HT29 gene expression and Treg phenotype, live bacterial cells were used.
HT29 cell line culture conditions. The epithelial intestinal cell line HT29 (ECACC no. 91072201), derived from human colon adenocarcinoma, was purchased from the European Collection of Cell Cultures (Salisbury, United Kingdom). The cell line was maintained in McCoy's medium supplemented with 3 mM L-glutamine, 10% (vol/vol) heat-inactivated fetal bovine serum (FBS), and a mixture of antibiotics to give final concentrations of 50 g/ml penicillin, 50 g/ml streptomycin, 50 g/ml gentamicin, and 1.25 g/ml amphotericin B. All media and supplements were obtained from Sigma. The incubations took place at 37°C in 5% CO 2 in an SL water-jacketed CO 2 incubator (Sheldon Mfg., Inc., Cornelius, OR). Culture media were changed every 2 days, and the cell line was trypsinized with 0.25% trypsin-EDTA solution (Sigma) following standard procedures. For gene expression experiments, as well as for the collection of bifidobacterium-conditioned HT29 supernatants (SN), 10 5 cells/ml were seeded in 24-well plates, incubated to confluence (a monolayer, reaching about 10 7 cells/ml), and used after 13 Ϯ 1 days. For monolayer integrity tests, the same procedure was used, but cells were grown in hanging cell culture inserts (0.4-m pore size, polyethylene terephthalate; Millipore Corporation, Billerica, MA) placed in 12-well microplates (Millipore).
(i) HT29 cell gene expression analysis. B. bifidum LMG13195 and B. breve IPLA 20004 were grown overnight in MRSc, harvested by centrifugation, washed twice with Dulbecco's phosphate-buffered saline (PBS) buffer, and resuspended in McCoy's medium without antibiotics. Five hundred microliters of bacterial suspension (5 ϫ 10 7 bacteria) or McCoy's medium without bacteria (control) was added to each well containing HT29 monolayers, previously washed twice with Dulbecco's PBS to remove antibiotics. Microplates were then incubated for 6 h at 37°C in 5% CO 2 . After incubation, the culture media were collected and centrifuged at 4,000 rpm for 15 min to eliminate bacterial cells, and these bifidobacterium-conditioned supernatants were stored at Ϫ80°C until being used for stimulation of peripheral blood mononuclear cells (PBMCs). Then, the HT29 monolayers were released in 500 l of RNA Protect cell reagent (Qiagen GmbH, Hilden, Germany) and kept frozen at Ϫ80°C until RNA extraction. Three independent experiments were carried out for each experimental condition.
RNA from HT29 cells was extracted by using the RNeasy Plus minikit (Qiagen) and QIAshredder homogenizer columns (Qiagen) following the manufacturer's instructions. RNA quality was monitored by gel electrophoresis, and it was quantified by using an Epoch apparatus (BioTek Instruments, Inc., Winoskii, VT). cDNA was synthesized using the Ambion WT expression kit (Applied Biosystems, Foster City, CA), and the hybridization was performed on Human Gene Expression arrays (GeneChip Human Gene 1.0 ST arrays; Affymetrix), following the protocols established by Affymetrix. Three independent experiments were carried out for each experimental condition. The microarray analyses were performed at the Parque Científico de Madrid (Campus de Cantoblanco, Madrid, Spain).
(ii) HT29 cell monolayer integrity. Suspensions of UV-killed B. bifidum LMG13195 and B. breve IPLA 20004 cells were harvested by centrifugation and resuspended in McCoy's medium without antibiotics. Then, 500 l of bacterial suspension (5 ϫ 10 7 bacteria) was added to each HT29 monolayer grown on the apical insert compartment (bacterium/HT29 cell ratio, 10:1) and 2 ml of fresh medium was added to the basolateral compartment. Plates were incubated at 37°C in 5% CO 2 in the Heracell 240 incubator (Thermo Electron LDD GmbH, Langenselbold, Germany) for 24 h. Transepithelial resistance (TER) was determined at different time points by using a Millicell ERS2 apparatus (Millipore). To calculate the resistance per area unit (⍀·cm 2 ), the TER value obtained for the inserts with monolayer (with or without bifidobacteria) was subtracted with background TER from the insert alone (without monolayer) and multiplied by the area of the insert. Results were expressed with regard to that obtained for the control (medium without bifidobacteria), which was arbitrarily set to 100%. Experiments were carried out in duplicated HT29 microplates, and in each experiment, the strains were also tested in duplicate.
PBMC culture conditions. Human peripheral blood mononuclear cells (PBMCs) were obtained from standard buffy coat preparations from routine blood donors (Asturian Blood Transfusion Center, Oviedo, Spain) by centrifugation over Ficoll-Hypaque gradients (Lymphoprep; Nycomed, Oslo, Norway) and extensive washing with PBS under sterile conditions. All blood donors (the numbers are specified in the figure legends) were healthy adult volunteers without any pathology or treatment. Approval for this study was obtained from the Regional Ethics Committee for Clinical Investigation. (ii) Flow cytometric analysis. Phenotypic studies of PBMCs were performed after staining with the appropriate monoclonal antibody (MAb) using a FACSCanto II flow cytometer (Becton Dickinson, BD Biosciences, San Diego, CA). Cells were stained with anti-CD25 (fluorescein isothio-
.5 conjugated), CD127 (PE-Cy7 conjugated) MAb or with the corresponding isotype-matched conjugated irrelevant MAb as a negative control. All MAbs were supplied by Pharmingen (BD Biosciences). Extracellular staining of CD4, CD25, CD127, and chemokine receptors was performed for 30 min at 4°C, and then cells were washed twice in staining buffer and resuspended in PBS. After that, cells were fixed, permeabilized, and intracellularly stained with anti-FOXP3 (PE conjugated) (clone PCH101) following the manufacturer's instructions (Foxp3/transcription factor staining buffer set; eBiosciences Inc., San Diego, CA). The analysis was based on cells of the living region defined using forward and side scatter. Cells were further gated according to the CD4 expression. A min-imum of 10,000 CD4 ϩ lymphocytes were acquired and analyzed using the FACSDiva software 6. high with respect to CD25 Ϫ T cells was analyzed by t test. The comparisons carried out between samples are described in the figure legend for each experiment. GraphPad Prism 5 software (GraphPad Software, San Diego, CA) and SPSS 18.0 software were used for all determinations, and a P value of Ͻ0.05 was considered significant.
RESULTS
B. bifidum LMG13195 affected the transcriptomic profile of HT29 cells. In order to characterize the effect of B. bifidum LMG13195 and B. breve IPLA 20004 on human intestinal epithelial cells, we analyzed the transcriptome profile of HT29 cells cultured for 6 h in the presence of these strains, compared with control HT29 cells (not exposed to bacteria), by using a Human Gene Expression Array. In general, although changes in gene expression were modest, both strains showed the ability to modulate the transcriptome of HT29 cells. Overall, at a significance level P Ͻ 0.01, the treatment of HT29 cells with B. bifidum LMG13195 induced a differential expression of 121 genes with respect to the control culture, while the culture with B. breve IPLA 20004 modified the expression of 173 genes. Interestingly, the treatment with B. bifidum LMG13195 showed an increased expression of diverse genes associated with immune responses to a higher degree than B. breve IPLA 20004 (see Table S1 in the supplemental material). Specifically, among the genes showing higher induction (Table 1) , we identified a number of genes coding for chemokines; thus, B. bifidum LMG13195 was able to increase the expression of CXCL10, CCL20, CXCL11, and CCL22 in HT29 cells. In addition, genes induced by interferon (IFN), involved in microbial defense in human mucosa, were also found to be increased, like those coding for IL-28 and IL-29, two IFN type III molecules.
B. bifidum LMG13195-conditioned HT29 supernatants influenced T-cell recruitment responses. We recently reported that DCs exposed to B. bifidum LMG13195 in vitro induce the polarization of naïve CD4 ϩ lymphocytes into functional CD25 high FOXP3 ϩ Treg cells (26) . Since HT29 cells increased the expression of immune mediators and chemotactic molecules after exposure to live bifidobacteria, we wanted to determine their possible involvement in the generation or recruitment of Treg cells, given that these lymphocytes may express receptors for specific chemokines. Thus, PBMCs from healthy individuals were cultured with the supernatants of HT29 cells previously incubated with B. bifidum LMG13195 (LMG13195-HT29 SN) HT29 SN) , or medium alone (Control-HT29 SN) for 5 days, and the expression of CD25, FOXP3, and CD127, as well as that of the chemokine receptors CCR3, CCR4, CCR6, and CXCR3, was analyzed by flow cytometry in CD4 ϩ lymphocytes before and after culture. Figure 1 shows that before culture, freshly isolated CD4
ϩ CD25 high cells, the natural Treg (nTreg) cell population, in addition to showing high FOXP3 and low CD127 levels, expressed CCR6, CCR4, and CCR3, but not CXCR3, so we used the CCR6 ϩ CCR4 ϩ CCR3 ϩ CXCR3 Ϫ phenotype as a chemokine receptor Treg marker (Fig. 2A) . Fig. 2A and B) . Similarly, the CCR6 ϩ CCR4 ϩ CCR3 ϩ CXCR3 Ϫ population, regardless of CD25 expression, increased after culture compared with freshly isolated cells (2.76% Ϯ 2.39%), but no significant differences were observed between the two bifidobacterium-HT29 SN treatments (LMG13195-HT29 SN, 4.54% Ϯ 0.81%; IPLA 20004-HT29 SN, 4.58% Ϯ 1.31%). Given that these chemokine receptors could also be expressed by CD25 low effector T cells (24) , which were also generated after stimulation with the different HT29 SN ( Fig. 2A) , we determined the amount of CCR6 ϩ CCR4 ϩ CCR3 ϩ CXCR3 Ϫ cells expressing high levels of CD25 ( Fig. 2A, red Fig. 2A, red cells) , whereas CCR4 high CCR6
high cells (a Th17-associated phenotype) (24) were mostly included in the CD25 low subset ( Fig. 2A, blue cells) , thus probably being effector T cells.
B. bifidum LMG13195 and B. breve IPLA 20004 enhanced intestinal barrier function. Finally, to characterize the effect of B. bifidum LMG13195 and B. breve IPLA 20004 on intestinal barrier function, we determined the TER of HT29 intestinal epithelia cell monolayers exposed to the UV-inactivated bifidobacteria at different times (Fig. 3) . After 3 h of coculture with the bacteria, an increase in the monolayer TER was already observed for the strain B. breve IPLA 20004, while strain B. bifidum LMG13195 did not show differences with regard to the control (medium without bacteria). However, at later incubation times (8 and 24 h), a significant increase in TER was observed for both microorganisms, this increase being significantly higher for B. breve IPLA 20004 than for B. bifidum LMG13195.
DISCUSSION
Commonly used probiotics include Bifidobacterium species, commensal microorganisms usually present in the gut of adult individuals where they could interact with intestinal epithelial cells. This interplay may modulate the local immune environment through, for instance, the modification of gene expression and the production of chemokines and other immune molecules by intestinal cells under both physiological and pathological conditions (15, 21, 38, 40) . However, the extent to which commensal bacteria regulate the expression of immune molecules by epithelial cells is chemokines (CCL20, CCL22, CXCL10, and CXCL11) and two type III interferon molecules (IL-28 and IL-29), important immune mediators that play key roles in host mucosa homeostasis and defense (47) . These data suggest that soluble factors and chemotactic cytokines derived from the combined effect of intestinal epithelial cells and B. bifidum LMG13195 contact could influence mucosal immunity and attract specific subsets to gut mucosa. Studies on transcriptional responses of human epithelial cells to probiotic bifidobacteria are scarce and inconclusive (35, 43) . More studies, however, have been performed with Lactobacillus strains, observing differences both in vitro (28, 30, 39) and in vivo (8, 45, 46) after bacterial treatment. In fact, the inducing effect on a number of genes coding for chemotactic cytokines observed in this work has also been described in in vivo studies with probiotic lactobacilli (8) .
Due to its relevant role in intestinal immunity, we considered especially interesting the finding about the increased expression of CCL20, previously reported after Lactobacillus johnsonii N6.2 stimulation of the epithelial cell line Caco-2 (22) . CCL20 (also known as macrophage inflammatory protein-3␣ [MIP-3␣]) is a chemokine constitutively expressed at a low basal level by a variety of normal human mucosa-associated tissues, especially in the gut mucosal epithelial cells (19, 32) . During normal development and immune homeostasis, CCL20 selectively attract CCR6-expressing lymphocytes and DCs (3, 13) to the mucosal surfaces, organizing lymphoid tissues, such as Peyer's patches, mesenteric lymph nodes, and GALT (9, 19) . Additionally, CCL20/CCR6-mediated signals can be strongly induced by proinflammatory stimuli, including cytokines (e.g., tumor necrosis factor alpha [TNF-␣]) and Toll-like receptor (TLR) agonists, originating from microbes (41), thus contributing to the recruitment of target cells to epithelial mucosal surfaces. Therefore, intestinal epithelial cells might have the capacity to link innate and acquired mucosal immunity through the upregulation of CCL20, which in turn recruited CCR6-expressing T cells, specifically, Th1, Th17, and Treg subsets.
In view of the capability of B. bifidum LMG13195 to increase HT29 gene transcription of chemotactic molecules that could activate and attract specific immune cell subsets to gut mucosa, and its ability to induce the polarization of naïve CD4 ϩ lymphocytes into functional CD25 high FOXP3 ϩ Treg cells through its effect on
DCs (26), we wanted to determine the possible contribution of epithelial cell exposure to this strain to the generation of Treg cells able to be recruited to the intestinal mucosa. The Treg population can be identified by its high expression of CD25 and the transcription factor FOXP3 and lack of the IL-7R alpha chain (CD127) (25, 42 
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high cells expressing chemokine receptor Treg markers, thus making possible their recruitment to the intestinal mucosa. Although some bacterial products could be present in supernatants without HT29 cells, in a previous work, we reported that diverse cell-free bifidobacterial culture supernatants were unable to induce significant responses in PBMCs (27) , suggesting that the results observed in this work came from the combined effects of the bacteria and the epithelial cells. These data are in agreement with the proposed Treg inducer ability of B. bifidum LMG13195 and support that an effect on the intestinal mucosa could be a mechanism by which this strain plays an active immunoregulatory role. In line with our findings, how the cross talk between human intestinal epithelial and immune cells helped in maintaining gut immune homeostasis was recently described. Iliev et al. reported that monocyte-derived DCs, conditioned with supernatants from Caco-2 or intestinal epithelial cells isolated from healthy donors, promoted the differentiation of tolerogenic DCs able to drive the development of gut-homing Treg cells, which were effective in suppressing T-cell proliferation in vitro and extremely potent in protecting against colitis in vivo (17). This evidence supports epithelial cells not only being a physical barrier but also playing an active role in the production of diverse factors which control DC function, Treg differentiation, and intestinal tolerance. In this sense, the effect of probiotics on Treg induction/recruitment to the mucosal surface would be therapeutically beneficial in controlling the excessive immune responses involved in chronic inflammation, mucosal allergies, and autoimmune diseases. Finally, in addition to the beneficial activities on the immune system, in the present work, we wanted to extend the understanding of the interaction between bifidobacteria and the gut mucosa. One previously described probiotic-related beneficial mechanism is to increase the physical resistance of the mucosa. In the present high , CD25 low , and CD25 Ϫ lymphocytes out of the CCR6 ϩ CCR4 ϩ CCR3 ϩ CXCR3 Ϫ population before (fresh cells) and after PBMC culture with the different HT29 SN. Statistical differences among groups were assessed by ANOVA for repeated measures; Tukey's posttests for multiple comparisons were conducted to determine which groups' pairs had different means. study, we observed that both B. bifidum LMG13195 and B. breve IPLA 20004 strains were able to increase the integrity of the HT29 monolayer in vitro, thus contributing to strengthening the gut barrier, this effect being more pronounced for IPLA 20004. Additionally, the adherence to human epithelial cells and cell lines is one of the most exhaustive tests used to indicate the increased ability of a probiotic strain to have transitory persistence in the colon. Interestingly, this trait could also be a way to connect the interaction between bifidobacteria and intestinal immune homeostasis. Previous experiments carried out by our group showed an extremely high adhesion rate of B. bifidum LMG13195 to HT29 cells (adhesion rate to HT29 cells of about 75%; González-Rodriguez et al., unpublished data) compared to B. breve IPLA 20004 (about 5.5% adhesion to HT29 cells) (2) . Thus, the greater capacity of B. bifidum LMG13195 to stay in contact with the epithelium could partially explain its ability to induce different characteristics on the HT29 supernatant, which, in turn, could influence the generation of CD4 ϩ CD25 high cells expressing chemokine receptor Treg markers, thus making possible their recruitment to the intestinal mucosa.
In summary, our results suggested a strengthening of the gut barrier through the interaction of the B. bifidum LMG13195 strain with colonocytes. This may lead to a specific environment at local epithelium promoting the induction of Treg cells expressing chemokine receptors that favor mucosal homing, an attractive goal in the prevention and treatment of diseases characterized by an overreaction of the immune system, such as autoimmune diseases, asthma, and allergy.
